<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>DNA methylation and other epigenetic phenomena appear to be relevant in the pathogenesis of several malignant disorders </plain></SENT>
<SENT sid="1" pm="."><plain>DNA methyltransferases add methyl groups to <z:chebi fb="1" ids="16040">cytosine</z:chebi>-phosphate-<z:chebi fb="1" ids="16235">guanine</z:chebi> (CpG) islandsleading to gene promoter silencing </plain></SENT>
<SENT sid="2" pm="."><plain>The DNA methyltransferases inhibitors <z:chebi fb="0" ids="2038">azacitidine</z:chebi> and <z:chebi fb="0" ids="50131">decitabine</z:chebi> have anti-<z:e sem="disease" ids="C0027651" disease_type="Neoplastic Process" abbrv="">tumor</z:e> activity against a broad range of <z:e sem="disease" ids="C0006826" disease_type="Neoplastic Process" abbrv="">malignancies</z:e>, but have been investigated mostly in <z:hpo ids='HP_0002863'>myelodysplastic syndrome</z:hpo> </plain></SENT>
<SENT sid="3" pm="."><plain>In addition, these agents have immunomodulatory effects that are under investigation in the allogeneic stem cell transplantation scenario </plain></SENT>
<SENT sid="4" pm="."><plain>Both drugs have been used in the perioperative period of allogeneic transplantations with varying degrees of success </plain></SENT>
<SENT sid="5" pm="."><plain>It has been hypothesized that low dose <z:chebi fb="0" ids="2038">azacitidine</z:chebi> may increase the graft-versus-<z:hpo ids='HP_0001909'>leukemia</z:hpo> effect and have a role in the maintenance of remission after allogeneic transplantation for myeloid <z:hpo ids='HP_0001909'>leukemias</z:hpo> </plain></SENT>
<SENT sid="6" pm="."><plain>It is also intriguing that this favorable effect might occur while mitigating <z:e sem="disease" ids="C0018133" disease_type="Disease or Syndrome" abbrv="GVH">graft-versus-host disease</z:e> </plain></SENT>
<SENT sid="7" pm="."><plain>Here we present a review of the rapidly growing field of epigenetic manipulation using hypomethylating agents in allogeneic transplantation </plain></SENT>
</text></document>